2607

SERUM THROMBOPOIETIN (TPO), INTERLEUKIN-6 (1L-6) AND INTERLCUKIN-11 (IL-11) IN CHILDHOOD LEUKEMIAS AND LYMPHOMAS

Ahmed, K. Mansour, *Osama, Elbaz,**Nabil Abdel-Razik, Hesham Abdel-Hady*and Abeer Ismael*

Hematology-Oncology Unit, Department of Pediatrics, *& Clinical Pathology Department**, Mansoura Faculty of Medicine, Egypt

Chemotherapy-induced thrombocytopenia is a major risk factor in cancer treatment, The thrombocytopenic cpisodes during the course of chemotherapy treatment may cause life threatening hemorrhages, also they may lead to delay of anticancer therapy or drug reduction. The serum levels of TPO, IL-6 and IL-11 were assayed by immunoreactive methods in 39 patients, diagnosed as acute leukemias (23 patients) and lymphomas (16 patient) at diagnosis and after induction chemotherapy as will as 20 normal children, as a control group.

Patients with acute leukemia were found to have a high serum level of TPO, correlated with the thrombocytopenia present in these patients both before and after chemotherapy. A statistically significant difference in the serum level of TPO levels, between these patients and the control group was present (P=0.000 in ALL group and P=0.001 in ANLL group). Also, a non significant difference in the TPO level before chemotherapy and its level after chemotherapy was present. (p=0.28 in ALL group and p=0.09 in ANLL group) While in patients with Hodgkin’s disease and those with Non-Hodgkin lymphoma, TPO level showed no significant difference from

the control group whether before or after chemotherapy and this was correlated with the normal platelet count in those patients.

As regared IL-6 and IL-1, the serum levels did not show any significant change in patients with ALL and AML whether before and after chemotherapy, however, a significant rise in IL-6 and IL-11 levels were observed in patients with HD and NHL both before and after chemotherapy. (p=0.005 and 0.008 for HD group) (p=0.000 and 0.013 for NHL group) .